The approval makes Wegovy the only GLP-1 therapy cleared to treat adults with metabolic dysfunction-associated ...

Madrigal Pharmaceuticals’ Rezdiffra has been approved in Europe for the treatment of MASH with moderate to advanced liver ...

In a significant breakthrough for the treatment of liver disease, Novo Nordisk's Wegovy has received U.S. approval for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) in ...

The move is likely part of the company’s goal to reduce costs as it faces increased competition in the GLP-1 space.

MDGL wins EU nod for Rezdiffra as the first and only approved MASH therapy. The drug's launch in Europe is expected in the fourth quarter of 2025.

This is one huge reason to believe in the future of Novo Nordisk (NYSE: NVO), the Danish company behind the immensely popular Wegovy obesity treatment. Last week the company earned a new feather in ...

Novo Nordisk may pursue layoffs as its new CEO focuses on efficiency while facing intensifying obesity drug competition.

The European Commission (EC) has granted conditional marketing authorization for Madrigal Pharmaceuticals' Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic metabolic ...

A draft copy of an upcoming MAHA report reveals a strategy in lockstep with recent HHS actions such as reviving the Task ...

Viking Therapeutics, Inc.'s obesity drug VK2735 results reveal no clear edge over leading competitors. Click for why this ...

The oral formulation led to up to 12.2% weight loss over three months, a weaker outcome versus late-stage treatments from Eli ...